Patents Assigned to Max-Delbrueck Centrum fuer Molekulare Medizin
-
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 10214530Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: February 24, 2016Date of Patent: February 26, 2019Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
Patent number: 10144782Abstract: The invention relates to humanized antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.Type: GrantFiled: April 30, 2015Date of Patent: December 4, 2018Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFTInventors: Felix Oden, Stephen Marino, Oliver Daumke
-
Patent number: 10118957Abstract: The invention pertains to a means for downregulating or inhibiting or mislocalizing CAR in a cardiac cell for treating/curing a patient who has suffered or is predisposed to suffering a myocardial infarction (MI) or preventing myocardial infarction or complications thereof.Type: GrantFiled: August 5, 2013Date of Patent: November 6, 2018Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Michael Gotthardt, Fabian Freiberg
-
Patent number: 10082499Abstract: The present invention relates to a method for preparation of labeled metabolic products, comprising the steps (a) providing a biological sample in vitro, (b) contacting the biological sample with a labeling buffer comprising a labeled substrate, wherein the substrate comprises at least one carbon atom and represents an educt or intermediate of a metabolic process of the biological sample and wherein the label is a stable isotope, (c) washing the biological sample using a wash-buffer, wherein said wash-buffer comprises a carbon resource such that the biological sample is precluded from carbon deficiency during said washing, wherein said carbon resource comprises the substrate according to step b), wherein said substrate in the wash-buffer may be labeled or unlabeled, (d) quenching the biological sample such that metabolic processes within the biological sample are slowed down or stopped and (e) extracting the labeled metabolic product from the biological sample.Type: GrantFiled: May 14, 2015Date of Patent: September 25, 2018Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Stefan Kempa, Matthias Pietzke, Christin Zasada
-
Publication number: 20180135032Abstract: The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transposon, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.Type: ApplicationFiled: November 3, 2017Publication date: May 17, 2018Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Zsuzsanna Izsvak, Zoltan Ivics, Lajos Mates, Namitha Manoj, Carmen-Anisia Judis, Andrea Katzer
-
Patent number: 9927423Abstract: The invention relates to a method for the identification of a channel modulator, such as an agonist or antagonist, that interacts with one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E and/or protein complexes thereof. The invention further relates to an isolated heteromeric protein complex comprising one or more or LRRC8A, LRRC8B, LRRC8C, LRRC8D and/or LRRC8E for use in such methods, in addition to kits suitable for carrying out such methods. The invention therefore relate preferably to the use of LRRC8 proteins and complexes thereof for the identification of VRAC (VSOAC) modulators.Type: GrantFiled: March 10, 2015Date of Patent: March 27, 2018Assignees: FORSCHUNGSVERBUND BERLIN E.V., MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Thomas Jentsch, Tobias Stauber, Felizia K. Voss
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20180051025Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: February 24, 2016Publication date: February 22, 2018Applicants: Max-Delbrück-Centrum für Molekulare Medizin, Forschungsverbund Berlin e.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Patent number: 9862755Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: March 25, 2014Date of Patent: January 9, 2018Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20170275590Abstract: The invention relates to method for cultivating stem cells in vitro, comprising the following steps: providing a sample comprising stem cells and cultivating the stem cells by subjecting the sample to a treatment for a first period of time. The treatment is carried out under hypothermic conditions having a defined temperature and a defined atmosphere, wherein the temperature does not exceed 15° C. and the atmosphere has an oxygen content not exceeding 21% (v/v). Thereby, the first period of time is 4 days to 4 weeks.Type: ApplicationFiled: August 25, 2015Publication date: September 28, 2017Applicants: CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Andreas MARG, Simone SPULER
-
Patent number: 9492495Abstract: The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and/or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and/or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease.Type: GrantFiled: May 16, 2011Date of Patent: November 15, 2016Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Philipp Hillmeister, Ivo Buschmann, Ferdinand Lenoble, Nora Gatzke
-
Patent number: 9409969Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: GrantFiled: February 9, 2010Date of Patent: August 9, 2016Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Patent number: 9272991Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.Type: GrantFiled: January 13, 2010Date of Patent: March 1, 2016Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
-
Patent number: 9238837Abstract: The invention relates to a method for determining the temporal phase of acute kidney injury, comprising obtaining a test sample from a subject and measuring the expression level of at least one biomarker selected from the group comprising Chac1, Birc5 and Angptl7. The invention also relates to a method for determining the early early phase, the late early phase, the severity and/or timing of acute kidney injury via analysis of the biomarkers Chac1, Birc5 and/or Angptl7, in addition to a test kit for carrying out said methods and antibodies directed against Chac1, Birc5 or Angptl7.Type: GrantFiled: June 17, 2011Date of Patent: January 19, 2016Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Kai Schmidt-Ott, Anne Wuebken
-
Patent number: 9234201Abstract: The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.Type: GrantFiled: March 2, 2012Date of Patent: January 12, 2016Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, CHARITÉ—UNIVERSITAETSMEDIZIN BERLINInventors: Ingolf Schimke, Annekathrin Haberland, Gerd Wallukat
-
Patent number: 9115404Abstract: The invention pertains to a RNA molecule transcribed form a long terminal repeat (LTR) sequence, comprising a sequence encoding a gene, such as CSF1R, and a sequence that is at least in part found in the LTR, in particular for detecting cancer in a subject.Type: GrantFiled: June 21, 2010Date of Patent: August 25, 2015Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCHInventors: Stephan Mathas, Björn Lamprecht, Bernd Dörken, Constanze Bonifer
-
Patent number: 9061058Abstract: The present invention relates generally to the field of molecular biology. More specifically, the present invention relates to expression systems for use in modulating the expression of protein coding target genes in vivo or in vitro. More specific, this invention relates to RNA polymerase III-based methods and systems for expression of therapeutic proteins in cells in vivo or in vitro.Type: GrantFiled: March 20, 2007Date of Patent: June 23, 2015Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Jehad Charo, Thomas Blankenstein
-
Patent number: 9040238Abstract: The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.Type: GrantFiled: June 22, 2010Date of Patent: May 26, 2015Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCHInventors: Michael Gotthardt, Norbert Hübner, Marion Lewis Greaser, Wei Guo
-
Patent number: 8974768Abstract: The present invention relates to compounds suitable as modulators of protein misfolding and/or protein aggregation. The compounds are particularly suitable as inhibitors of amyloid aggregate formation and/or modulators of amyloid surface properties, and/or as activators of degradation or reduction of amyloid aggregates.Type: GrantFiled: March 23, 2011Date of Patent: March 10, 2015Assignee: Max-Delbrueck-Centrum fuer Molekulare MedizinInventors: Erich Wanker, Thomas Wiglenda, Julius Tachu Babila, Annett Boeddrich, Michael Schmidt, Franziska Schiele
-
Patent number: 8969080Abstract: Disclosed is the use of inhibitors of ?-catenin expression or activity or modulators downregulating ?-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells.Type: GrantFiled: October 5, 2009Date of Patent: March 3, 2015Assignee: Max-Delbrueck-Centrum fuer Molekulare MedizinInventors: Martin Bergmann, Joerg Huelsken, Walter Birchmeier, Makoto Mark Taketo
-
Patent number: 8842897Abstract: The invention relates to a method for the quantification of the image quality of at least one tomographic picture of an object, wherein at least one tomographic cross-sectional image is produced using a cross-sectional imaging method, in particular a magnetic resonance tomography method. As a measure of the image quality in a cross-sectional image, an image detail is measured, in particular the width of a boundary between two adjacent areas is determined, in particular with the signal intensity remaining constant in each such area, in particular said signal intensity remaining constant at least within predetermined/predeterminable boundaries.Type: GrantFiled: March 5, 2010Date of Patent: September 23, 2014Assignee: Max-Delbrueck-Centrum fuer Molekulare Medizin (MDC)Inventors: Fabian Hezel, Thoralf Niendorf